The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, wh ...

These White House deals will require the nine midsize pharma companies to provide MFN prices to state Medicaid programmes nationally.

The US FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).

Aficamten improves cardiac structure and diastolic function, strengthening its case as a targeted therapy for nonobstructive HCM.

The Australia-based STAREE trial is the first of its kind demonstrating the preventative effects of statins in older patients.

The new Mounjaro approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.

Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.

Researchers call for further exploration of xylitol’s impact on heart health as its use in food and pharma continues to rise.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

AusperBio Therapeutics and Ausper Biopharma have closed a Series C funding round worth $120m to support the development of new therapies for chronic hepatitis B.

The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.